跳至主要内容
临床试验/EUCTR2007-005079-32-AT
EUCTR2007-005079-32-AT进行中(未招募)1 期

Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra

Medical University of Vienna0 个研究点目标入组 20 人开始时间: 2007年10月31日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Biopsy proven renal amyoidosis
  • 2.Serum Amyloid A concentration greater than 25mg/l
  • 3.Estimated GFR between 30 to 90ml/min
  • 4.Men or women aged >18years
  • 5.Provision of informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Estimated GFR < 30ml/min
  • 2.Kidney disease other than renal amyloidosis
  • 3.Child bearing potential with lack of a reliable method of contraception.
  • 4.Poor compliance
  • 5.Medical history that might limit the individual’s ability to take the trial treatment for the duration of the study.
  • 6.Simultanous administration of TNF-blocking agents (etanercept, adalimumab, and infliximab)

研究者

相似试验

Treatment of secondary renal amyloidosis A with the... | 临床试验